INTRODUCTION
Liver fibrosis is one of the main characteristics of chronic hepatitis B (CHB). Accurate assessment of liver fibrosis is vital for predicting disease progression and choo sing optimal treatment timing. Liver biopsy (LB) is the current gold standard for evaluating the liver fibrosis sta ge. However, repeatedly utilizing LB in patients is very difficult because of its invasiveness and complications [1] . Therefore, noninvasive methods have been developed 522 WJCC|www.wjgnet.com Wang L et al . ALT and non-invasive fibrosis tests to assess liver fibrosis when the riskbenefit tradeoff does not favor a LB [2] . According to the EASLALEH Clinical Practice Gu idelines, noninvasive methods were recently divided into serum biomarkers and liver stiffness (LS) measu rements [3] . Because of their high applicability (> 95%) and good interlaboratory reproducibility, serum biomar kers are widely used in clinical practice [3] . Over the past few years, many convenient noninvasive fibrosis tests have been established, including the aspartate aminotransfe rase (AST)toplatelet (PLT) ratio index (APRI) [4] and the fibrosis index based on 4 factors (FIB4) [5] . Moreover, the APRI and FIB4 were recommended by the WHO for evaluation of liver fibrosis in resourcelimited regions [6] . However, most noninvasive fibrosis tests have been de veloped primarily based on chronic hepatitis C patients, and their use in assessing liver fibrosis in CHB patien ts is controversial [79] . Therefore, more data should be collected regarding the use of these established non invasive tests to predict liver fibrosis in CHB patients. Recently, Lemoine et al [10] constructed the gammaglu tamyl transpeptidase (GGT)toPLT ratio (GPR) model based on CHB patients, but its diagnostic performance assessing liver fibrosis varied among different studies [11, 12] . Alanine aminotransferase (ALT) is considered an accurate and valuable routine indicator of liver inflam mation. Many studies have reported the influence of serum ALT levels on LS [13, 14] . According to the EASLALEH Clinical Practice Guidelines for CHB [3] , LS measurem ents should be interpreted in patients with an elevated ALT level and should not be used in patients with ALT levels more than 10 times the upper limit of normal (ULN). However, no report has investigated the effects of changes in CHB patients' serum ALT levels on the diagnostic performances of these noninvasive tests. For these reasons, the aim of this study was to explore the effect of ALT on the diagnostic performance of non invasive fibrosis tests in CHB patients.
MATERIALS AND METHODS

Patients
The study included treatmentnaive CHB patients who underwent LB from 20122017 in the Shengjing Hos pital affiliated with China Medical University. CHB was defined as hepatitis B surface antigenpositive lasting at least six months. The exclusion criteria were as follows: (1) coinfection with human immunodeficiency virus; (2) other liver disease (other viral hepatitis, autoimmune liver disease, drug hepatitis and liver failure); (3) signi ficant alcohol intake (> 20 g/d for women and > 30 g/d for men) for more than 5 years; (4) tumor; (5) liver tra nsplantation; and (6) hematological diseases.
The study was approved by the Medical Ethics Com mittee of Shengjing Hospital of China Medical University and was performed in accordance with the guidelines of the 1975 Declaration of Helsinki. Written informed con sent for the LB was obtained from all patients.
Laboratory data and histology
Laboratory data, including the blood test results (PLT), liver biochemistry (ALT; aspartate aminotransferase, AST; alkaline phosphatase, ALP; γglutamyltransferase, GGT and cholesterol), HBV serological marker levels (HBsAg; hepatitis B envelope antigen, HBeAg; anti bodies against HBsAg, antiHBs; antibodies against HBeAg, antiHBe and antibodies against HBcAb, anti HBc), blood coagulation (international normalized ratio, INR) and HBV DNA levels, were recorded for all included patients.
All liver specimens were a minimum of 10 mm with at least five portal tracts. A histopathological assess ment was performed by two expert pathologists who were unaware of the patient's clinical characteristics. According to Scheuer's classification score, liver fibrosis was classified from 0 to 4 [15] .
Non-invasive fibrosis tests and calculation formulas
Noninvasive prediction methods and calculation for mulas were applied for the CHB patients according to the original reported formulas with the original cut off values for the APRI, FIB4, Forns index [16] , GPR and King's score [17] . The formulas of these noninvasive tests are as follows: APRI = AST(/ULN)/ PLT (10 
Statistical analysis
Continuous and abnormal variables are expressed as the median (interquartile range, IQR), and categorical data are expressed as the frequency and percenta ge; the data were compared using the KruskalWallis test. Spearman's rank correlation was used to analy ze the liver fibrosis stages and the noninvasive test results. The diagnostic performances of these non invasive tests were assessed by receiver operating characteristic (ROC) curve analysis. The diagnostic performances of each test for the assessment of sig nificant fibrosis, advanced fibrosis and cirrhosis are described as the areas under the receiver operating characteristics curve (AUROCs) with 95% confidence intervals (95%CIs) and the diagnostic accuracy. All Pvalues were 2sided, and any value of P < 0.05 was considered statistically significant. The data analysis was performed using SPSS, version 22.0 (SPSS Inc., Chicago, IL, United States) and the GraphPad Softwa re, version 7.0 (GraphPad Prism Inc., San Diego, CA, United States).
RESULTS
Study population
From January 2012 to July 2017, 1262 biopsyproven patients with liver disease were assessed in the study. Among them, 575 patients were excluded according to the exclusion criteria, and 88 patients were excluded because of insufficient liver tissue and clinical data. Finally, 599 CHB patients were included in the cohort (Figure 1 ). The median (IQR) age of the patients was 37 (2944) years, and 349 (58.3%) patients were male. In all, 96 (16%) patients had significant fibrosis (≥ S2), 54 (9%) had advanced fibrosis (≥ S3), and 38 (6.3%) had cirrhosis (S4). The clinical parameters and stages of fibrosis are shown in Table 1 .
Effects of ALT on clinical factors in patients with CHB
To detect the effect of ALT on noninvasive fibrosis te sts, the patients were divided into the following three groups: normal ALT (ALT ≤ 40), slightly elevated ALT (40 < ALT ≤ 80) and elevated ALT (ALT > 80). The ba selines for these three groups are shown in Table 1 .
The ALT levels were significantly correlated with AST (r = 0.878), GGT (r = 0.565), HBV DNA (r = 0.363) and HBsAg (r = 0.137) (P < 0.05 for all). Significant ne gative associations were also found between the ALT level and age (r = 0.206) and male sex (r = 0.195) (P < 0.05 for all). Other clinical factors, including cho lesterol, INR and PLT, had no association with the ALT level (P > 0.05 for all).
Effects of ALT on the fibrosis scores of the non-invasive fibrosis tests
In addition, the ALT levels were positively correlated with the fibrosis stage (r = 0.141), APRI (r = 0.762), GPR (r = 0.545), King's score (r = 0.615), FIB4 (r = 0.125) and Forns index (r = 0.107) (P < 0.05 for all). In creasing ALT levels were significantly associated with an increased fibrosis stage (P < 0.05).
The patients with ALT > 80 had the highest fibro sis scores, whereas the lowest fibrosis scores were ob served for patients with ALT ≤ 40. In general, CHB patients with higher ALT levels had significantly higher fibrosis scores on the noninvasive tests (P < 0.05 for all) except for the Forns index (P = 0.081) ( Table 1) . Moreover, the patients with higher ALT levels showed significantly higher fibrosis scores on the noninvasive tests than those with lower ALT levels at the same stage of liver fibrosis (P < 0.05 for all) except for Forns index and FIB4 at S1, S2 and S4 ( Table 2) .
Effects of ALT on the diagnostic performance of the non-invasive fibrosis tests
A summary of the diagnostic performances of these noninvasive tests, including the AUROCs, 95%CIs and Pvalues in the different ALT groups for the prediction of significant fibrosis, advanced fibrosis and cirrhosis, are shown in Table 3 and Figure 2 . Wang L et al . ALT and non-invasive fibrosis tests (Table 3) .
However, evaluating the effect of ALT on nonin vasive fibrosis tests based only on one AUROC from one stage is difficult, and a more comprehensive and systematic assessment is greatly need. Thus, a grad ing system based on AUROCs to evaluate the effect of ALT on the prediction of liver fibrosis (≥ S2, ≥ S3 and S4) at different ALT levels was developed (Table 4) . According to the AUROC grading system, noninvasive fibrosis tests were grade A in CHB patients with ALT ≤ 40 U/L and grade B in patients with 40 < ALT ≤ 80 U/L and ALT > 80 U/L. Although the noninvasive tests in patients with 40 < ALT ≤ 80 U/L and ALT > 80 U/L were both grade B, the grading points in the patients with 40 < ALT ≤ 80 U/L were higher than those in the patients with ALT > 80 U/L (Table 4) . Above all, the grading points of the AUROCs decreased in a stepwise manner with the increase in the serum ALT level.
Effects of ALT on the diagnostic accuracy of the noninvasive fibrosis tests
The relationship between the diagnostic accuracy and serum ALT was also evaluated using the cut off value as the original threshold. For the ≥ S2 prediction, the diagnostic accuracies of the APRI (lower cut off value 0.5), APRI (higher cut off value 1. The above results indicate that the noninvasive tests for the prediction of liver fibrosis (≥ S2, ≥ S3 and S4) exhibited the highest diagnostic accuracy for patients in the ALT ≤ 40 U/L group and the lowest diagnostic accuracy for patients in the ALT > 80 U/L group, except for the Forns index (using the lower cut off values) for the ≥ S2 prediction and APRI (using the higher cut off values) for the S4 prediction (Table 3 and Figure 3 ). The diagnostic accuracy of the noninvasive tests decreased in a stepwise manner with the increase in the serum ALT level. 
DISCUSSION
In this study, we evaluated the diagnostic performances of five convenient noninvasive tests for liver fibrosis among a large cohort of treatmentnaive CHB patients with different ALT levels. To the best of our knowledge, this study is the first to thoroughly analyze the effect of ALT on the diagnostic performance and accuracy of noninvasive tests in CHB patients. The results showed that elevated serum ALT levels negatively affected the diagnostic performance of the noninvasive fibrosis te sts. These noninvasive fibrosis tests showed a better diagnostic accuracy in CHB patients with normal ALT levels than in patients with abnormal ALT levels. One important finding of our study was that CHB patients with higher ALT levels showed significantly higher fibrosis scores in the noninvasive tests even at the same liver fibrosis stage. The result demonstrated that noninvasive tests could overestimate liver fibro sis in some CHB patients with elevated ALT. In other words, patients who had elevated ALT with no or mild fibrosis would be considered to have significant fibrosis, advanced fibrosis or cirrhosis. For example, the GPR, which had the highest AUROCs for the noninvasive test to predict cirrhosis in the study, showed that 6/272 (2.21%) CHB patients with normal ALT, 19/190 (10%) patients with slightly elevated ALT and 41/137 (29.9%) patients with elevated ALT would be misdiagnosed (i.e., approximately 10% of CHB patients with slightly elevated ALT and 30% of patients with elevated ALT would be misclassified as having cirrhosis). ALT flares often occur during the progression of CHB, especially for patients with acute or active hepatitis. Thus, the effect of ALT should be considered when assessing liver fibrosis using noninvasive tests.
To detect the effect of ALT on noninvasive tests, we compared the diagnostic performance and accura cy of the noninvasive tests in different ALT groups. In this study, most AUROCs (11/15) for prediction of ≥ S2, ≥ S3 or S4 by the noninvasive tests were greater than 0.75 in patients with normal ALT but less than 0.75 (12/15) in patients with elevated ALT. Thus, the tests showed a slightly higher performance for the CHB patients with normal ALT than for the patients with el evated ALT.
To further examine the effect of ALT on the nonin vasive tests, an overall analysis of AUROCs should be conducted in patients with different ALT levels. Howev er, the performance of AUROCs varies among different fibrosis tests, etiologies and cohorts [10, 11] . Therefore, evaluating the diagnostic performance of noninvasive fibrosis tests using one AUROC from one stage is difficult. A simple, comprehensive and systematic assessment is more reasonable and acceptable; thus, the AUROC grading system for the prediction of liver fibrosis was developed. In this study, we comprehensively evaluated the effect of ALT on five common noninvasive fibrosis tests based on the AUROC grading system. The ability of the AUROCs to predict liver fibrosis decreased with the increase in the ALT level. Additionally, studies have reported that elevated ALT can influence the diagnostic performances of noninvasive fibrosis tests, although most of these studies have focused on ≥ S2 or S4 [1820] . In our study, the effect of ALT on the AUROCs of the noninvasive fibrosis tests among three fibrosis stages (≥ S2, ≥ S3 and S4) were all included. The AUROCs for prediction of ≥ S2, ≥ S3 and S4 were more stable in patients with ALT ≤ 40 U/L. Similarly, the best diagnostic accuracy of the non invasive tests was found in patients with a normal ALT level, whereas the accuracy was lowest in patients with elevated ALT. The diagnostic accuracy of these non invasive tests decreased in a stepwise manner with the increase in the ALT level. In patients with normal ALT, the AUROCs of these noninvasive tests for the diagnosis of cirrhosis ranged from 0.79 to 0.833 with a diagnostic accuracy range from 93.01% to 94.44% when the cut off value was the original threshold. How ever, for CHB patients with elevated ALT, the AUROCs of these noninvasive tests for the diagnosis of cirrhosis ranged from 0.662 to 0.719 with a diagnostic accuracy range from 42.34% to 77.37% when the cut off value was the original threshold. From the above results, we can infer that the diagnostic performances of the non invasive tests were less reliable in CHB patients with elevated ALT levels.
The phenomenon may contribute to liver inflamm ation. Liver fibrosis is the process by which damaged hepatocytes are repaired and is a product of dysreg ulated inflammation in chronic viral hepatitis [21] . Liver inflammation can influence LS [14] . Moreover, systemic inflammation can serve as a degenerating factor for in trahepatic hypertension in cirrhosis [22] . The serum ALT level is the most direct and valuable marker that reflects liver inflammation in the clinic. To some extent, more severe liver inflammation is associated with greater ALT elevation [23] , which has more impact on the noninvasive tests. This phenomenon may be the main reason why the noninvasive tests showed better diagnostic perfor mances in patients with normal ALT.
This study had several limitations. First, this study was a singlecenter retrospective study. A multicenter study will be performed in the future. Second, we com pared only some of the more convenient noninvasive diagnostic tests. Other noninvasive diagnostic tests and LS measurements will be evaluated in future studies.
In conclusion, the ALT level has a significant effect on the diagnostic performance and accuracy of non invasive fibrosis tests. The ALT level should be consi dered before performing these noninvasive tests.
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